CSL have a history of diversifying their product range to cover more human conditions each year. The question of the affordability of these products is more a question for governments and communities than CSL.
I'm sure that a marketing assessment is a component part of CSL's product pipeline development process.
If the market price is limited the products won't be developed and people with any affected conditions will continue to suffer. That's the dilemma facing the governments and communities that form CSL's customer base.
CSL possible pull back to low $200's, page-73
-
- There are more pages in this discussion • 510 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.15 |
Change
0.550(0.18%) |
Mkt cap ! $149.7B | |||
| Open | High | Low | Value | Volume |
| $308.93 | $311.00 | $307.00 | $86.88M | 280.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 28 | $307.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.17 | 2 | 2 |
View Market Depth
| Last trade - 13.22pm 15/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |